Norwegian Targovax ASA (Oslo) has reported tremendous safety, immunogenicity, and one-year survival data, of in the modified cohort of the TG01 trial in resected pancreatic cancer patients.
Sanofi is investing €170m to expand its vaccine manufacturing site in Val de Reuil, France, which produces 900 million vaccine doses worldwide each year.
Britishresearchers have identified interleukin 36 (IL-36) as a druggable proinflammatory driver of psoriasis. Because of its very targeted effects of antibodies directed against the cytokine they want to start clinical tests in man.
German-Israeli Neurim Pharmaceuticals announced top line efficacy results of its insomnia drug PedPRM in children with autism spectrum disorders (ASD).
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2017-10-11 09:07:412017-10-11 09:07:41Neurim tables Phase III data of insomnia drug
French cancer drug encapsulation specialist Erytech Pharma SA wants to raise US$100m (€85m) in an IPO at NASDAQ and a subsequent private placement outside Northern America to finance pivotal trials of eryaspase in ALL and pancreatic cancer.
https://european-biotechnology.com/wp-content/uploads/2024/04/Erytech.png436843Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2017-10-10 06:18:382017-10-10 06:18:38Erytech Pharma set to raise US$100m in IPO and private placement
https://european-biotechnology.com/wp-content/uploads/2024/04/uniqure_Gene_therapy_NIH.jpg371495Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2017-10-09 06:06:322017-10-09 06:06:32uniQure’s AMT-130 receives FDA Orphan Drug Designation in Huntington’s disease
https://european-biotechnology.com/wp-content/uploads/2024/04/Microsart_Sartorius_PDW.PNG450800Maren Kühr/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMaren Kühr2017-10-08 00:00:002024-04-02 15:51:46Advanced system for touch-free membrane transfer
Cancer immunotherapy specialist Immatics Biotechnologies GmbH (Tuebingen, Germany) raised US$58m in a Series E financing round led by German investors dievini Hopp BioTech Holding and AT Impf as well as Wellington Partners and new investor Amgen.
https://european-biotechnology.com/wp-content/uploads/2024/04/Zika.jpg21001500h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2017-10-04 10:08:372017-10-04 10:08:37Avillion names new Chief Business Officer
Targovax reports 100% one-year survival in pancreatic cancer trial
Latest NewsNorwegian Targovax ASA (Oslo) has reported tremendous safety, immunogenicity, and one-year survival data, of in the modified cohort of the TG01 trial in resected pancreatic cancer patients.
Sanofi invests €170m to expand flu jab facility
Latest NewsSanofi is investing €170m to expand its vaccine manufacturing site in Val de Reuil, France, which produces 900 million vaccine doses worldwide each year.
Researchers describe alternative psoriasis target
Latest NewsBritish researchers have identified interleukin 36 (IL-36) as a druggable proinflammatory driver of psoriasis. Because of its very targeted effects of antibodies directed against the cytokine they want to start clinical tests in man.
Neurim tables Phase III data of insomnia drug
Latest NewsGerman-Israeli Neurim Pharmaceuticals announced top line efficacy results of its insomnia drug PedPRM in children with autism spectrum disorders (ASD).
Erytech Pharma set to raise US$100m in IPO and private placement
Latest NewsFrench cancer drug encapsulation specialist Erytech Pharma SA wants to raise US$100m (€85m) in an IPO at NASDAQ and a subsequent private placement outside Northern America to finance pivotal trials of eryaspase in ALL and pancreatic cancer.
uniQure’s AMT-130 receives FDA Orphan Drug Designation in Huntington’s disease
Latest NewsAs first gene therapy ever, AMT-130 has been granted FDA Orphan Drug status in Huntington’s Disease.
Advanced system for touch-free membrane transfer
ProductsMicrosart ® @media Advanced System for Touch-free Membrane Transfer.
Promethera Biosciences partners with Shibuya Corp
Latest NewsPromethera Biosciences and Shibuya collaborate to establish a breakthrough cell therapy manufacturing platform.
Immatics raises $58m
Latest NewsCancer immunotherapy specialist Immatics Biotechnologies GmbH (Tuebingen, Germany) raised US$58m in a Series E financing round led by German investors dievini Hopp BioTech Holding and AT Impf as well as Wellington Partners and new investor Amgen.
Avillion names new Chief Business Officer
AppointmentsLate-stage pharmaceuticals financing and co-development specialist Avillion LLP has named Kathryn J. Gregory Chief Business Officer.